Pharmaceutical & medical


SCALING UP WITH MODULAR PRODUCTION


zenon is also developed compliant with IEC 62443 industrial safety standard and offers state of the art security against unauthorised access. One common issue raised against personalised medicine is the collection and storage of patient’s genetic information, so protecting confidentiality should be a fundamental concept in production. The zenon Module Type Package (MTP) Suite can optimise production efficiency by allowing a task to be subdivided into small modules that can be standardised. The system’s intelligent interconnection can


Instrumentation Monthly June 2023


connect these modules in multiple ways to suit the operation - it is essentially plug-and-produce. The platform’s features are not just advantageous in the manufacturing stage - it can even prove useful in large molecule drug design and development. It meets IPSE GAMP 5 Guidelines for software category 4, allowing swifter system validation. zenon also meets the requirements of GMP and FDA 21 Part 11 for strictly validated production environments. The quicker validation and consistent compliance allows pharmaceutical companies to develop, design and test vaccines and


biopharmaceuticals with a much faster turnaround time. Medicine is evolving, with advanced technologies and revolutionary new therapeutics changing the face of the industry. To keep this momentum and to produce personalised medicine on a larger scale, digital transformation will be essential. Smarter processes and automation will allow manufacturers to expand into this growing field while remaining compliant to its strict regulations, allowing them to offer more pioneering new treatments than ever before.


COPA-DATA www.copadata.com 67


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82